tailieunhanh - EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In traditional anti-cancer therapy, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been proven to be beneficial for patients with EGFR mutations. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN